Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

Employees

1,081

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	HK$1.000	0.00%	0
06/08/26	HK$1.000	0.00%	152,000
05/08/26	HK$1.000	-2.91%	144,000
04/08/26	HK$1.030	+0.98%	72,000
03/08/26	HK$1.020	-1.92%	0

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 12:08:13 07/08/2026 +04			5-day change	1st Jan Change
1.000 ^HKD	0.00%		0.00%	-18.03%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI

Market Cap	1.3B 1.51B 192M 167M 156M 143M 267M 18.3B 272M 1.83B 716M 9.19B 722M 706M 30.33B	P/E 2024	3.06x	P/E 2025	7.83x
Enterprise Value	-432M -503M -64.15M -55.6M -51.9M -47.63M -89.23M -6.11B -90.77M -609M -239M -3.07B -241M -236M -10.12B	EV / Sales 2024	0.14x	EV / Sales 2025	-0.06x
Free-Float	32.62%	Yield 2024	5.16%	Yield 2025	5.16%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI
03-27	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share	RE
03-27	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026	CI
22/08/25	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/08/25	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025	CI
22/08/25	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln	RE
31/07/25	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025	CI
23/05/25	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024	CI
23/05/25	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024	CI
28/03/25	Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million	RE
28/03/25	Dawnrays Pharmaceutical Limited Proposes Special Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025	CI

20/04/21	Dawnrays Pharmaceutical : Form of proxy for use at the Annual General Meeting of the Company to be held on Friday, 28 May 2021 (or at any adjournment thereof)	PU
20/04/21	Dawnrays Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	PU
23/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
22/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
21/09/20	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU

Dawnrays Pharmaceutical (Holdings) Limited Stock

Stocks

2348

KYG2687M1006

Pharmaceuticals

Valuation: Dawnrays Pharmaceutical (Holdings) Limited

Chart: Dawnrays Pharmaceutical (Holdings) Limited

Latest news : Dawnrays Pharmaceutical (Holdings) Limited

Press Releases: Dawnrays Pharmaceutical (Holdings) Limited

Quotes and Performance

Course Extremes

Managers and Directors: Dawnrays Pharmaceutical (Holdings) Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Current month	-3.85%
3 months	-12.28%
6 months	-15.97%
Current year	-18.03%

1 week	1	1.03
1 month	0.99	1.06
Current year	0.98	1.22
1 year	0.98	1.4
3 years	0.98	1.47
5 years	0.98	1.82
10 years	0.84	2.88

Manager	Title	Age	Since
Li Wei Yu CEO	Chief Executive Officer	56	13/09/2024
Yi jun Wu DFI	Director of Finance/CFO	61	-
Michelle Li IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Kei Ling Li CHM	Chairman	77	01/10/2002
Yung Lai Hung BRD	Director/Board Member	81	01/10/2002
Hong Man Leung BRD	Director/Board Member	51	01/11/2005

Date	Insider	Type	Main position	Quantity	% Market Cap.
24/11/25	Kei Ling Li	Other	Chairman	8,000	0.0005%
24/11/25	Fortune United Group Ltd	Other	Company	8,000	0.0005%
03/11/25	Yung Lai Hung	Other	Director	52,000	0.0035%

	2024	2025
Net sales	1.06B 1.23B 157M 136M 127M 117M 219M 14.98B 223M 1.49B 586M 7.52B 591M 578M 24.83B	1.23B 1.43B 183M 158M 148M 136M 254M 17.39B 259M 1.73B 680M 8.73B 686M 671M 28.82B
Net income	565M 658M 83.85M 72.68M 67.84M 62.26M 117M 7.98B 119M 796M 312M 4.01B 315M 308M 13.23B	214M 249M 31.76M 27.53M 25.7M 23.58M 44.18M 3.02B 44.94M 302M 118M 1.52B 119M 117M 5.01B
Net Debt	-1.57B -1.83B -233M -202M -189M -173M -325M -22.23B -330M -2.22B -869M -11.16B -877M -858M -36.83B	-1.73B -2.01B -256M -222M -207M -190M -357M -24.41B -363M -2.43B -954M -12.25B -963M -942M -40.44B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	0.00%	0.00%	-26.47%	-18.03%	192M
ELI LILLY AND COMPANY	-0.52%	+2.66%	+58.86%	+163.79%	1,062B
JOHNSON & JOHNSON	+0.88%	+1.34%	+51.97%	+53.36%	619B
ABBVIE INC.	+0.89%	-4.42%	+25.34%	+66.55%	431B
ROCHE HOLDING AG	+0.71%	+3.93%	+47.75%	+38.58%	358B
NOVARTIS AG	+0.64%	-0.63%	+36.39%	+41.44%	293B
ASTRAZENECA PLC	+0.39%	-6.48%	+7.62%	+9.04%	247B
AMGEN INC.	+1.51%	+6.01%	+44.36%	+68.92%	219B
NOVO NORDISK A/S	+3.92%	-7.80%	+5.39%	-42.52%	200B
GILEAD SCIENCES, INC.	+1.80%	+1.47%	+20.79%	+69.31%	162B
Average	+0.98%	-1.71%	+27.20%	+45.04%	359.25B
Weighted average by Cap.	+0.62%	-0.83%	+41.60%	+78.43%